Shares of Metsera Inc. (MTSR) have gained 6.8% over the past four weeks to close the last trading session at $35.32, but ...

Methode Electronics posted adjusted loss of 77 cents per share, missing market estimates of earnings of 4 cents per share, ...

Merck & Co. agreed on Wednesday to acquire Verona Pharma for $107 per American Depository Share (ADS) for a total transaction ...

Metsera is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could ...

In the SPAC space, Nasdaq maintained a dominant position with a 95% win rate for business combinations and hosted 94% of all eligible SPAC IPOs in the first half of 2025, raising $10.6 billion and ...

MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related events, with consistent findings in further analyses, according to new ...

Ireland’s premier life sciences celebration recognises industry excellence with 217 attendees witnessing record-breaking ...

Treatment with mifepristone led to improved glycemic control and weight loss in patients with poorly controlled T2D and hypercortisolism, according to new data from the CATALYST trial.

The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the ...